Whalesbook
Court Pauses FSSAI Ashwagandha Leaf Restriction
The Karnataka High Court has placed a temporary halt on an FSSAI advisory that limited the use of Ashwagandha leaves and their extracts in food and supplements. This judicial intervention provides immediate relief to eight companies that had challenged the advisory.
Regulatory Overreach Questioned
The FSSAI advisory, issued on April 16, aimed to permit only Ashwagandha roots and their extracts, a change from prior practices linked to a Ministry of Ayush notification. The companies challenging the ban, including Kerry Inc. and its subsidiary Sami-Sabinsa Group, argue that such restrictions should not be imposed through an advisory. They contend that formal amendments to the Food Safety and Standards Act, 2006, are required. Kerry Group has a long history of using Ashwagandha leaves without prior FSSAI objections.
The companies also assert that the Ministry of Ayush notification lacks sufficient scientific evidence to connect Ashwagandha leaf consumption with safety concerns. This legal dispute highlights a conflict between recognizing traditional medicine and enforcing stringent food safety regulations.
Potential Risks and Future Outlook
The FSSAI and Ministry of Ayush can seek to overturn the interim order at the next hearing on June 8. If regulatory bodies present strong scientific evidence of safety risks or argue for the advisory's legality, the companies could face renewed restrictions. Prolonged legal battles may also create operational uncertainty, potentially affecting investment and product development.
Competitors not involved in the challenge might gain a temporary advantage. The case sets a precedent for how regulatory changes are implemented in the nutraceutical industry and the level of evidence required to support them. The sector will be closely watching the upcoming hearing for its impact on future regulatory approaches to herbal ingredients.